A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and preliminary efficacy of two formulations of the Latanoprost-PPDS in subjects with ocular hypertension or open-angle glaucoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mati Therapeutics Inc.
• Treatments: Latanoprost

Criteria

Inclusion Criteria:

• Subjects over 18 years of age diagnosed with ocular hypertension or open-angle glaucoma

• Subjects who have a best corrected visual acuity of 20/100 or better

Exclusion Criteria:

• Subjects who wear contact lenses

• Subjects who have uncontrolled medical conditions

• Subjects requiring chronic topical artificial tears, lubricants, and/or requiring any other chronic ocular topical medications

• Subjects who have a history of chronic or recurrent inflammatory eye disease